Drugs /

amg 650

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for amg 650

Amg 650 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating amg 650, 1 is phase 1 (1 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for amg 650 clinical trials.

Breast carcinoma, endometrial serous adenocarcinoma, and high grade fallopian tube serous adenocarcinoma are the most common diseases being investigated in amg 650 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Amg 650
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating amg 650 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
amg-650, amg650
Drug Target(s) [2]:
KIF18A

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.